Uso de probióticos en síndrome de intestino irritable y enfermedad inflamatoria intestinal: una revisión de la literatura
DOI:
https://doi.org/10.22516/25007440.141Palabras clave:
Enfermedades inflamatorias del intestino, estado nutricional, probióticos, síndrome del colon irritable, suplementos dietéticosResumen
Introducción: El síndrome de intestino irritable (SII) y la enfermedad inflamatoria intestinal (EII), son motivos de consulta frecuente. Usualmente su tratamiento se hace en primer nivel de atención, con ajuste de estilo de vida y cambios dietarios. Los tratamientos farmacológicos tienen eficacia limitada e importantes efectos secundarios, por lo que existe un interés creciente en terapias diferentes como el uso de probióticos.
Métodos: Se realizó una revisión de la literatura en las bases de datos Medline y Embase buscando estudios que asociaran suplementos nutricionales, con SII o EII, haciendo énfasis en probióticos.
Resultados: De un total de 1598 referencias, 43 cumplieron criterios finales de inclusión. El uso de probióticos en SII y EII sugiere ser una terapia que ayuda a mantener los periodos de remisión de enfermedad, mejorar la calidad de vida y atenuar el proceso fisiopatológico.
Conclusiones: El uso de probióticos y prebióticos podría ser una alternativa de soporte nutricional en pacientes seleccionados.
Descargas
Lenguajes:
esAgencias de apoyo:
Lafrancol S.A.S.Referencias bibliográficas
Hungin a. PS, Mulligan C, Pot B, Whorwell P, Agréus L, Fracasso P, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice - An evidence-based international guide. Aliment Pharmacol Ther 2013, 38:864–86. doi: https://doi.org/10.1111/apt.12460
Marteau P, Seksik P, Shanahan F. Manipulation of the bacterial flora in inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2003,17:47–61. doi: https://doi.org/10.1053/bega.2002.0344
Otero W, Gomez M. Síndrome de intestino irritable. Rev Col Gastroenterol 2005, 20:72–83.
Gómez Álvarez DF, Morales Vargas JG, Rojas Medina LM a, Mújica Oviedo SC, Camacho López PA, Rueda Jaimes GE. Factores sociosanitarios y prevalencia del síndrome del intestino irritable según los criterios diagnósticos de Roma III en una población general de Colombia. Gastroenterol Hepatol 2009,32:395–400. doi: https://doi.org/10.1016/j.gastrohep.2009.01.177
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012,10:712–21. doi: https://doi.org/10.1016/j.cgh.2012.02.029
Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol 2015, 21:3072–84. doi: https://doi.org/10.3748/wjg.v21.i10.3072
Cash BD. Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome. Curr Med Res Opin 2014, 30:1405–15. doi: https://doi.org/10.1185/03007995.2014.908278
Basso P, Bonfa G, Nardini V. Classical and recent advances in the treatment of inflammatory bowel diseases. Brazilian J Med Biol Res 2015,48:96–107. doi: https://doi.org/10.1590/1414-431X20143774
Pineda Ovalle LF. Enfermedad inflamatoria intestinal en Colombia . ¿Está cambiando nuestro perfil epidemiológico? Rev Col Gastroenterol 2010, 25:235–8.
Silverberg M, Satsangi J, Ahmad T, Arnott I, Bernstein C, Brant S, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005,19:5–36. doi: https://doi.org/10.1155/2005/269076
Verbeke K, Boesmans L, Boets E. Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation? Proc Nutr Soc 2014, 73:490–7. doi: https://doi.org/10.1017/S0029665114000639
Orel R. Probiotics and prebiotics in inflammatory bowel disease. Gastroenterol Hepatol 2014,30:419–25.
Bafutto M, Almeida J, Leite N, Costa M, Oliveira E, Resende-Filho J. Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii. Arq gastroenterol 2013,50:304–9. doi: https://doi.org/10.1590/S0004-28032013000400012
Pineton De Chambrun G, Neut C, Chau A, Cazaubiel M, Pelerin F, Justen P, et al. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig Liver Dis 2015,47:119–24. doi: https://doi.org/10.1016/j.dld.2014.11.007
Wong RK, Yang C, Song G-H, Wong J, Ho K-Y. Melatonin regulation as a possible mechanism for probiotic (VSL#3) in irritable bowel syndrome: a randomized double-blinded placebo study. Dig Dis Sci 2015, 60:186–94. doi: https://doi.org/10.1007/s10620-014-3299-8
Pedersen N, Andersen NN, Végh Z, Jensen L, Ankersen DV, Felding M, et al. Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J Gastroenterol 2014, 20:16215–26. doi: https://doi.org/10.3748/wjg.v20.i43.16215
Jafari E, Vahedi H, Merat S, Momtahen S, Riahi A. Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. Arch Iran Med 2014,17:466–70.
Fan Y, Chen S. A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial. J Zhejiang Univ Sci B. 2006, 7:987–91. doi: https://doi.org/10.1631/jzus.2006.B0987
Lorenzo-Zú-iga V. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol 2014, 20:8709. doi: https://doi.org/10.3748/wjg.v20.i26.8709
Urgesi R, Casale C, Pistelli R, Rapaccini GL, De Vitis I. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox??) in patients with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2014, 18:1344–53.
Sisson G, Ayis S, Sherwood R a., Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. Placebo in the irritable bowel syndrome - A 12 week double-blind study. Aliment Pharmacol Ther 2014, 40:51–62. doi: https://doi.org/10.1111/apt.12787
Cappello C, Tremolaterra F, Pascariello A, Ciacci C, Iovino P. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS): Effects on symptoms, colonic transit and quality of life. Int J Colorectal Dis 2013, 28:349–58. doi: https://doi.org/10.1007/s00384-012-1552-1
Stevenson C, Blaauw R, Fredericks E, Visser J, Roux S. Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome. Nutrition 2014,30:1151–7. doi: https://doi.org/10.1016/j.nut.2014.02.010
Ludidi S, Jonkers DM, Koning CJ, Kruimel JW, Mulder L, Van Der Vaart IB, et al. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol Motil 2014, 705–14. https://doi.org/10.1111/nmo.12320
Søndergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Ekesbo R. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol 2011, 46:663–72. https://doi.org/10.3109/00365521.2011.565066
Abbas Z, Yakoob J, Jafri W, Ahmad Z, Azam Z, Usman MW, et al. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome. Eur J Gastroenterol Hepatol 2014, 26:630-9. https://doi.org/10.1097/meg.0000000000000094
Choi CH, Jo SY, Park HJ, Chang SK, Byeon J-S, Myung S-J. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 2011, 45:679–83. https://doi.org/10.1097/MCG.0b013e318204593e
Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroentérologie Clin Biol 2008,32:147–52. https://doi.org/10.1016/j.gcb.2007.06.001
Simrén M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I, et al. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome - a randomized, double-blind, controlled study. Aliment Pharmacol Ther 2010,31:218–27.
Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life - A double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011,33:1123–32. https://doi.org/10.1111/j.1365-2036.2011.04633.x
Kruis W, Chrubasik S, Boehm S, Stange C, Schulze J. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 2012, 27: 467–74. https://doi.org/10.1007/s00384-011-1363-9
Roberts LM, McCahon D, Holder R, Wilson S, Hobbs FDR. A randomised controlled trial of a probiotic "functional food" in the management of irritable bowel syndrome. BMC Gastroenterol 2013,13:45. https://doi.org/10.1186/1471-230X-13-45
Tiequn B, Guanqun C, Shuo Z. Therapeutic effects of Lactobacillus in treating irritable bowel syndrome: a meta-analysis. Intern Med 2015,54:243–9. https://doi.org/10.2169/internalmedicine.54.2710
Jadhav S, Shandilya U, Kansal V. Exploring the ameliorative potential of probiotic Dahi containing Lactobacillus acidophilus and Bifidobacterium bifidum on dextran sodium sulphate induced colitis in mice. J Dairy Res 2013,80:21–7. https://doi.org/10.1017/S0022029912000684
Krag A, Munkholm P, Israelsen H, Von Ryberg B, Andersen K, Bendtsen F. Profermin is efficacious in patients with active ulcerative colitis - A randomized controlled trial. Inflamm Bowel Dis 2013,19:2584–92. https://doi.org/10.1097/01.MIB.0000437046.26036.db
Guslandi M, Giollo P, Testoni P. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003,15:697–8. https://doi.org/10.1097/00042737-200306000-00017
Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, et al. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999,13:1103–8. https://doi.org/10.1046/j.1365-2036.1999.00560.x
Ishikawa H, Matsumoto S, Ohashi Y, Imaoka A, Setoyama H, Umesaki Y, et al. Beneficial effects of probiotic Bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: A randomized controlled study. Digestion 2011,84:128–33. https://doi.org/10.1159/000322977
Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003, 22:56–63. https://doi.org/10.1080/07315724.2003.10719276
Fujimori S, Gudis K, Mitsui K, Seo T, Yonezawa M, Tanaka S, et al. A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis. Nutrition 2009, 25:520–5. https://doi.org/10.1016/j.nut.2008.11.017
Tsuda Y, Yoshimatsu Y, Aoki H, Nakamura K, Irie M, Fukuda K, et al. Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol. 2007, 42:1306–11. https://doi.org/10.1080/00365520701396091
Boudeau J, Glasser A, Julien S, Colombel J, Darfeuille-Michaud A. Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther 2003, 18:45–56. https://doi.org/10.1046/j.1365-2036.2003.01638.x
Fujimori S, Tatsuguchi A, Gudis K, Kishida T, Mitsui K, Ehara A, et al. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol 2007, 22:1199–204. https://doi.org/10.1111/j.1440-1746.2006.04535.x
Borruel N, Carol M, Casellas F, Antolín M, de Lara F, Espín E, et al. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002, 51:659–64. https://doi.org/10.1136/gut.51.5.659
Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in Maintenance Treatment of Crohn' s Disease. Dig Dis Sci 2000, 45:1462–4.
https://doi.org/10.1023/A:1005588911207
Benjamin J, Hedin C, Koutsoumpas A, Ng S, McCarthy N, Hart A, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 2011, 60:923–9. https://doi.org/10.1136/gut.2010.232025
Begtrup LM, de Muckadell OBS, Kjeldsen J, Christensen RD, Jarbøl DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome-a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 2013, 48:1127–35. https://doi.org/10.3109/00365521.2013.825314
Ki Cha B, Mun Jung S, Hwan Choi C, Song I, Woong Lee H, Joon Kim H, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2010, 46:220–7. https://doi.org/10.1097/MCG.0b013e31823712b1
Iacovu M, Tan V, Muir J, Gibson P. The low FODMAP diet and its application in east and southeast Asia. J Neurogastroenterol Motil 2015, 21:459–70. https://doi.org/10.5056/jnm15111
Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 2014, 1–8.
Yoon S, Lee J, Na G, Lee K, Lee Y. Low-FODMAP formula improves diarrhea and nutritional status in hospitalized patients receiving enteral nutrition: a randomized, multicenter, double-blind clinical trial. Nutr journal 2015,14:116. https://doi.org/10.1186/s12937-015-0106-0
Richman E, Rhodes JM. Review article: evidence-based dietary advice for patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013,38:1156–71. https://doi.org/10.1111/apt.12500
Rembacken B, Snelling M, Hawkey P, Chalmers D, Axon T. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 1999, 354:635–9. https://doi.org/10.1016/S0140-6736(98)06343-0
Sang LX, Chang B, Zhang WL, Wu XM, Li XH, Jiang M. Remission induction and maintenance effect of probiotics on ulcerative colitis: A meta-analysis. World J Gastroenterol 2010,16:1908–15. https://doi.org/10.3748/wjg.v16.i15.1908
Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006,101:1581–90. https://doi.org/10.1111/j.1572-0241.2006.00734.x
Williams E, Stimpson J, Wang D, Plummer S, Garaiova I, Barker M, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther2009, 29:97–103. https://doi.org/10.1111/j.1365-2036.2008.03848.x
Otero A, Bohórquez MC, Rosselli D. Y ¿dónde está el artículo?: cómo buscar la literatura científica relevante. Rev Colomb Psiquiatr 2003;32:391-402.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
| Estadísticas de artículo | |
|---|---|
| Vistas de resúmenes | |
| Vistas de PDF | |
| Descargas de PDF | |
| Vistas de HTML | |
| Otras vistas | |
